REN and type 2 diabetes mellitus: SGLT2is are recommended for the treatment of patients with T2DM and CKD (eGFR ≥ 30 mL/min/1.73 m2 and UACR > 30 mg/g), given their nephroprotective effects via the renin–angiotensin–aldosterone system [64].